

AGENDA

Cambridge Biosafety Committee Thursday, May 16th, 2024 – 3:00 pm 119 Windsor Street

Zoom registration link for public access:

https://cambridgema.zoom.us/webinar/register/WN v PEkGcpTheyGVLwi6BAhQ

Presentations

- 1. **Delphia Therapeutics** (Tori Frank, Stuart Farnham) will present a request for a new **BSL-2 ONLY** permit for their proposed facility at **One Kendall Square**, **Bldg 1400W Suite 302**
- Clasp Therapeutics (Eli Graber, Gill Kingsbury, Nicole Reardon) will present a request for a new BSL-2 ONLY permit for their proposed facility at One Kendall Square, Bldg 700, Suite 7-202

Old Business/Inspection Reports

- 4/19 Atavistik Bio (101 CambridgePark Drive, Suite 3000) relocation BSL-2 ONLY permit
- 4/23 Marlinspike Therapeutics (150 CambridgePark Drive, 2nd Floor) new BSL-2 ONLY permit
- 4/30 Moderna, Inc. (325 Binney Street) relocation BSL-2 ONLY permit
- 5/3 Regeneron Cell Medicines (60 Binney Street) new BSL-2 ONLY permit

New Business

On the recommendation of the Massachusetts Water Resources Authority (MWRA) Dr. Kevin Esvelt (MIT Media Lab) has requested that the Cambridge Biosafety Committee vote to assent to a pilot program expected to initially last approximately one month during which your team will put nucleic acid tracers (synthetic DNA packaged inside a non-infectious bacteriophage capsid) down the drain in homes and laboratories at various times during the day. Samples will be collected from Deer Island to look for the presence of the tracer. This tracer compound has non-infectious, non-replicating bacteriophage particles. Documentation of the approval from MWRA, which has formal authority over releases into the wastewater system and the proposed study have been sent to Committee members.

Adjourn



